These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8294165)

  • 1. Pharmacokinetics of linsidomine (SIN 1) after single and multiple intravenous short infusions in patients with renal insufficiency.
    Sennesael J; Verbeelen D; Degré S; Unger P; Stolear JC; Ostrowski J; von Hattingberg HM; Gaertner W
    Int J Clin Pharmacol Ther Toxicol; 1993 Nov; 31(11):533-41. PubMed ID: 8294165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of intravenous administration of nitroglycerin and SIN-1 or molsidomine on epicardial arterial diameter in patients with stable coronary heart disease].
    Münzel T; Kurz S; Heitzer T; Luhmann C; Just H
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():38-41. PubMed ID: 7968900
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetic variability of nimodipine disposition after single and multiple oral dosing to hypertensive renal failure patients: parametric and nonparametric population analysis.
    Terziivanov D; Atanasova I; Dimitrova V; Robeva R; Unger S; Mück W
    Int J Clin Pharmacol Ther; 1999 Aug; 37(8):404-12. PubMed ID: 10475143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Coronary dilatation after intracoronary administration of SIN-1 and intravenous molsidomine administration].
    Hug J; Hasenfuss G; Wollschläger H; Just HJ; Bonzel T
    Med Klin (Munich); 1994 Jul; 89 Suppl 2():34-7. PubMed ID: 7968899
    [No Abstract]   [Full Text] [Related]  

  • 5. [Acute hemodynamic effects of SIN-1 and isosorbide dinitrate in stable left ventricular failure: a comparative double-blind, cross-over study].
    Himbert D; Spreux-Varoquaux O; Jaeger P; Himbert C; Cohen-Solal A; Advenier C; Gourgon R
    Ann Cardiol Angeiol (Paris); 1992 Oct; 41(8):455-62. PubMed ID: 1298186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamics, tolerability, and pharmacokinetics of linsidomine (SIN-1) infusion during the acute phase of uncomplicated myocardial infarction.
    Foucher-Lavergne A; Kolsky H; Spreux-Varoquaux O; Delonca J; Beaufils P
    J Cardiovasc Pharmacol; 1993 Dec; 22(6):779-84. PubMed ID: 7509893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor agent in animal model and in patients with impaired renal function.
    Ikeda M; Furukawa H; Imamura H; Shimizu J; Ishida H; Masutani S; Tatsuta M; Kawasaki T; Satomi T
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):25-32. PubMed ID: 12111108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
    Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
    Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of fleroxacin in renal impairment.
    Weidekamm E
    Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Improved kidney function with intravenous prostaglandin E1 in patients with terminal heart failure].
    Wutte M; Hülsmann M; Berger R; Rödler S; Frey B; Stanek B; Pacher R
    Wien Klin Wochenschr; 1998 Jul; 110(13-14):473-8. PubMed ID: 9746960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of intravenous nitroglycerin after administration of sildenafil citrate to men with coronary artery disease: a double-blind, placebo-controlled, randomized, crossover trial.
    Parker JD; Bart BA; Webb DJ; Koren MJ; Siegel RL; Wang H; Malhotra B; Jen F; Glue P
    Crit Care Med; 2007 Aug; 35(8):1863-8. PubMed ID: 17522570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between plasma milrinone concentration and renal function in patients with cardiac disease.
    Hasei M; Uchiyama A; Nishimura M; Mashimo T; Fujino Y
    Acta Anaesthesiol Scand; 2008 Aug; 52(7):991-6. PubMed ID: 18477069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of molsidomine.
    Rosenkranz B; Winkelmann BR; Parnham MJ
    Clin Pharmacokinet; 1996 May; 30(5):372-84. PubMed ID: 8743336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study to evaluate the pharmacokinetics of oral 5-fluorouracil and eniluracil after concurrent administration to patients with refractory solid tumours and varying degrees of renal impairment (FUMA1005).
    O'Donnell A; Punt CJ; Judson I; Van Maanen L; Suttle AB; Ertel P; Beale P
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):58-66. PubMed ID: 12497207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver function and pharmacokinetics of molsidomine and its metabolite 3-morpholinosydnonimine in healthy volunteers.
    Wildgrube HJ; Ostrowski J; Chamberlain J; Gärtner W; Stockhausen H
    Arzneimittelforschung; 1986 Jul; 36(7):1129-33. PubMed ID: 3768083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD.
    Kowalsky SF; Echols M; Schwartz MT; Bailie GR; McCormick E
    Clin Nephrol; 1993 Jan; 39(1):53-8. PubMed ID: 8428409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.
    Türck D; Weber W; Sigmund R; Budde K; Neumayer HH; Fritsche L; Rominger KL; Feifel U; Slowinski T
    J Clin Pharmacol; 2004 Feb; 44(2):163-72. PubMed ID: 14747425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
    Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
    Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.